Table 1 Demographic and clinicopathological characteristics of patients in the modified intention-to-treat population
Characteristic | Exp-group (n = 122) | Con-group (n = 120) |
|---|---|---|
Age (years) | 57.8 ± 8.4 | 58.2 ± 8.7 |
BMI (kg/m2) | 22.3 ± 3.0 | 22.7 ± 3.4 |
ECOG performance status | ||
0 | 84 (68.9%) | 85 (70.8%) |
1 | 38 (31.1%) | 35 (29.2%) |
ASA grading | ||
I | 78 (63.9%) | 74 (61.7%) |
II | 37 (30.3%) | 38 (31.7%) |
III | 7 (5.7%) | 8 (6.7%) |
Comorbidities | ||
None | 81 (66.4%) | 74 (61.7%) |
≥1 | 41 (33.6%) | 46 (38.3%) |
Neoadjuvant chemotherapy | ||
Yes | 33 (27.0%) | 35 (29.2%) |
No | 89 (73.0%) | 85 (70.8%) |
Postoperative adjuvant therapy | ||
Capecitabine | 10 (8.2%) | 8 (6.7%) |
CapeOX | 51 (41.8%) | 49 (40.8%) |
mFOLFOX6 | 11 (9.0%) | 9 (7.5%) |
None | 50 (41.0%) | 54 (45.0%) |
Tumor size (cm) | 3.5 ± 1.3 | 3.3 ± 1.5 |
Tumor location | ||
Anterior | 28 (23.0%) | 33 (27.5%) |
Lateral | 57 (46.7%) | 50 (41.7%) |
Posterior | 37 (30.3%) | 37 (30.8%) |
Tumor height (cm) | 7.4 ± 2.3 | 7.5 ± 2.4 |
Proximal margin (cm) | 10.1 ± 2.1 | 10.1 ± 1.6 |
Distal margin (cm) | 3.1 ± 1.2 | 3.0 ± 1.3 |
Retrieved lymph nodes (No.) | 19.0 ± 9.7 | 17.2 ± 8.4 |
Metastatic lymph nodes (No.) | 1.3 ± 4.0 | 1.7 + 3.9 |
Histology | ||
Differentiated | 109 (89.3%) | 105 (87.5%) |
Poorly differentiated | 13 (10.7%) | 15 (12.5%) |
TME grading classification | ||
I | 118 (96.7%) | 116 (96.7%) |
II | 4 (3.3%) | 4 (3.3%) |
III | 0 | 0 |
Pathologic T stage | ||
1 | 14 (11.5%) | 16 (13.3%) |
2 | 24 (19.7%) | 27 (22.5%) |
3 | 40 (32.8%) | 32 (26.7%) |
4 | 44 (36.1%) | 45 (37.5%) |
Pathologic N stage | ||
0 | 78 (63.9%) | 68 (56.7%) |
1 | 30 (24.6%) | 30 (25.0%) |
2 | 14 (11.5%) | 22 (18.3%) |
Pathologic TNM stage | ||
I | 33 (27.0%) | 35 (29.2%) |
II | 45 (36.9%) | 33 (27.5%) |
III | 44 (36.1%) | 52 (43.3%) |
